Long-term clinical outcomes of patients with hematologically unexplained cytopenia after routine assessment: A single center study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Long-term clinical outcomes of patients with hematologically unexplained cytopenia after routine assessment : A single center study. / Johansen, Morten Munk; Andersen, Michael Asger; Grønbaek, Kirsten; Hansen, Jakob Werner.
In: European Journal of Haematology, Vol. 101, No. 5, 2018, p. 595–603.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Long-term clinical outcomes of patients with hematologically unexplained cytopenia after routine assessment
T2 - A single center study
AU - Johansen, Morten Munk
AU - Andersen, Michael Asger
AU - Grønbaek, Kirsten
AU - Hansen, Jakob Werner
N1 - © 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
PY - 2018
Y1 - 2018
N2 - OBJECTIVE: We investigated mortality and long-term development of malignant hematological disease, cancer, liver-, renal-, and rheumatic disease in patients with unexplained cytopenia (UC).METHODS: We screened all patients referred to the outpatient clinic at the Department of Hematology, Rigshospitalet, Copenhagen, with a suspected myeloid neoplasm from June 2009 to the end of 2012. Through registry linkage, we obtained information on hospital-based ICD-10 diagnoses and survival. We estimated cumulative incidences of disease and hazard ratios of all-cause mortality using the Aalen-Johansen estimator and Cox regression. We compared incidences and mortality with a control cohort.RESULTS: Among 1820 referrals, 221 had UC. The UC group had a 5-year cumulative incidence of malignant hematological disease of 8.91% (CI 95%: 4.98-12.84) compared to 0.93(CI 95%: 0.32-1.55) in the matched controls. In addition, UC patients had higher incidences of cancer, liver, and rheumatic disease. Mortality was higher in UC patients compared to the matched controls with a HR of 1.43 [P = 0.038, CI 95%: 1.02-2.00] adjusted for comorbidity, sex, and age. Most of the mortality and morbidity were ascribed to patients 50 years or older.CONCLUSIONS: Unexplained cytopenia patients had a higher incidence of malignant hematological-, cancer-, liver-, and rheumatic disease and increased mortality compared to the general population.
AB - OBJECTIVE: We investigated mortality and long-term development of malignant hematological disease, cancer, liver-, renal-, and rheumatic disease in patients with unexplained cytopenia (UC).METHODS: We screened all patients referred to the outpatient clinic at the Department of Hematology, Rigshospitalet, Copenhagen, with a suspected myeloid neoplasm from June 2009 to the end of 2012. Through registry linkage, we obtained information on hospital-based ICD-10 diagnoses and survival. We estimated cumulative incidences of disease and hazard ratios of all-cause mortality using the Aalen-Johansen estimator and Cox regression. We compared incidences and mortality with a control cohort.RESULTS: Among 1820 referrals, 221 had UC. The UC group had a 5-year cumulative incidence of malignant hematological disease of 8.91% (CI 95%: 4.98-12.84) compared to 0.93(CI 95%: 0.32-1.55) in the matched controls. In addition, UC patients had higher incidences of cancer, liver, and rheumatic disease. Mortality was higher in UC patients compared to the matched controls with a HR of 1.43 [P = 0.038, CI 95%: 1.02-2.00] adjusted for comorbidity, sex, and age. Most of the mortality and morbidity were ascribed to patients 50 years or older.CONCLUSIONS: Unexplained cytopenia patients had a higher incidence of malignant hematological-, cancer-, liver-, and rheumatic disease and increased mortality compared to the general population.
U2 - 10.1111/ejh.13146
DO - 10.1111/ejh.13146
M3 - Journal article
C2 - 30027609
VL - 101
SP - 595
EP - 603
JO - European Journal of Haematology
JF - European Journal of Haematology
SN - 0902-4441
IS - 5
ER -
ID: 215042332